Product
surufatinib
Aliases
HMPL-012, sulfatinib
1 clinical trial
1 indication
Indication
TumorClinical trial
A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib (HMPL-012), Previously Named Sulfatinib in Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-04-25